Cognition Therapeutics (CGTX) IPO Opens Fractionally Higher

Today's IPO for Cognition Therapeutics, Inc.(NASDAQ: CGTX) opened for trading at $12.15 after pricing 3,768,116 shares of its common stock at a public offering price of $12.00 per share.

B. Riley Securities, Inc. is acting as the lead bookrunning manager and Oppenheimer & Co. is acting as joint bookrunning manager. Troutman Pepper Hamilton Sanders LLP is representing the Company and McGuireWoods LLP is representing the underwriters.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases

You May Also Be Interested In

• Jones Ventures INTL Acquisition1 prices $200M IPO on Nasdaq
• Apnimed files for initial public offering on Nasdaq
• Tailored Brands files for IPO on Nasdaq